Dan Peer

List of Publications by Citations

140 papers	14,378 citations	48 h-index	119 g-index
160 ext. papers	16,437 ext. citations	11.3 avg, IF	6.89 L-index

#	Paper	IF	Citations
140	Nanocarriers as an emerging platform for cancer therapy. *Nature Nanotechnology*, **2007**, 2, 751-60	28.7	6530
139	Progress and challenges towards targeted delivery of cancer therapeutics. *Nature Communications*, **2018**, 9, 1410	17.4	976
138	Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. *Science*, **2008**, 319, 627-30	33.3	428
137	Nanoparticle hydrophobicity dictates immune response. *Journal of the American Chemical Society*, **2012**, 134, 3965-7	16.4	342
136	The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation. *Biomaterials*, **2010**, 31, 6867-75	15.6	280
135	Polysaccharides as building blocks for nanotherapeutics. *Chemical Society Reviews*, **2012**, 41, 2623-40	58.5	257
134	Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 4095-100	11.5	232
133	Nanoparticles for imaging, sensing, and therapeutic intervention. *ACS Nano*, **2014**, 8, 3107-22	16.7	211
132	Loading mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models. *International Journal of Cancer*, **2004**, 108, 780-9	7.5	200
131	Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal Doxorubicin in syngeneic and human xenograft mouse tumor models. *Neoplasia*, **2004**, 6, 343-53	6.4	181
130	RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice. *Molecular Therapy*, **2010**, 18, 370-6	11.7	175
129	Hyaluronan-coated nanoparticles: the influence of the molecular weight on CD44-hyaluronan interactions and on the immune response. *Journal of Controlled Release*, **2011**, 156, 231-8	11.7	171
128	RNAi-based nanomedicines for targeted personalized therapy. *Advanced Drug Delivery Reviews*, **2012**, 64, 1508-21	18.5	125
127	Paclitaxel-clusters coated with hyaluronan as selective tumor-targeted nanovectors. *Biomaterials*, **2010**, 31, 7106-14	15.6	123
126	A modular platform for targeted RNAi therapeutics. *Nature Nanotechnology*, **2018**, 13, 214-219	28.7	118
125	Localized RNAi therapeutics of chemoresistant grade IV glioma using hyaluronan-grafted lipid-based nanoparticles. *ACS Nano*, **2015**, 9, 1581-91	16.7	118
124	Next-Generation Lipids in RNA Interference Therapeutics. *ACS Nano*, **2017**, 11, 7572-7586	16.7	114

123	Special delivery: targeted therapy with small RNAs. *Gene Therapy*, **2011**, 18, 1127-33	4	111
122	Systemic Gene Silencing in Primary T Lymphocytes Using Targeted Lipid Nanoparticles. *ACS Nano*, **2015**, 9, 6706-16	16.7	106
121	Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes. *Nature Communications*, **2018**, 9, 4493	17.4	106
120	On the issue of transparency and reproducibility in nanomedicine. *Nature Nanotechnology*, **2019**, 14, 629-635	28.7	92
119	Altering the immune response with lipid-based nanoparticles. *Journal of Controlled Release*, **2012**, 161, 600-8	11.7	88
118	CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy. *Science Advances*, **2020**, 6,	14.3	86
117	Cell-specific uptake of mantle cell lymphoma-derived exosomes by malignant and non-malignant B-lymphocytes. *Cancer Letters*, **2015**, 364, 59-69	9.9	83
116	Emerging Trends in Micro- and Nanoscale Technologies in Medicine: From Basic Discoveries to Translation. *ACS Nano*, **2017**, 11, 5195-5214	16.7	78
115	Reshaping the future of nanopharmaceuticals: ad iudicium. *ACS Nano*, **2011**, 5, 8454-8	16.7	75
114	A Combinatorial Library of Lipid Nanoparticles for RNA Delivery to Leukocytes. *Advanced Materials*, **2020**, 32, e1906128	24	75
113	Modulation of drug resistance in ovarian adenocarcinoma using chemotherapy entrapped in hyaluronan-grafted nanoparticle clusters. *ACS Nano*, **2014**, 8, 2183-95	16.7	74
112	Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models. *Cancer Research*, **2004**, 64, 7562-9	10.1	72
111	Paving the Road for RNA Therapeutics. *Trends in Pharmacological Sciences*, **2020**, 41, 755-775	13.2	72
110	Precision nanomedicine in neurodegenerative diseases. *ACS Nano*, **2014**, 8, 1958-65	16.7	70
109	Hyaluronan is a key component in cryoprotection and formulation of targeted unilamellar liposomes. *Biochimica Et Biophysica Acta - Biomembranes*, **2003**, 1612, 76-82	3.8	69
108	Triggered ferroptotic polymer micelles for reversing multidrug resistance to chemotherapy. *Biomaterials*, **2019**, 223, 119486	15.6	68
107	Hyaluronan-grafted particle clusters loaded with Mitomycin C as selective nanovectors for primary head and neck cancers. *Biomaterials*, **2011**, 32, 4840-8	15.6	65
106	Immunotoxicity derived from manipulating leukocytes with lipid-based nanoparticles. *Advanced Drug Delivery Reviews*, **2012**, 64, 1738-48	18.5	64

105	Corneal gene therapy. *Journal of Controlled Release*, **2007**, 124, 107-33	11.7	64
104	Personalized Hydrogels for Engineering Diverse Fully Autologous Tissue Implants. *Advanced Materials*, **2019**, 31, e1803895	24	64
103	Hyaluronan grafted lipid-based nanoparticles as RNAi carriers for cancer cells. *Cancer Letters*, **2013**, 334, 221-7	9.9	60
102	Delivering the right message: Challenges and opportunities in lipid nanoparticles-mediated modified mRNA therapeutics-An innate immune system standpoint. *Seminars in Immunology*, **2017**, 34, 68-77	10.7	58
101	Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, E16-22	11.5	57
100	Omics-based nanomedicine: the future of personalized oncology. *Cancer Letters*, **2014**, 352, 126-36	9.9	55
99	Transforming Nanomedicines From Lab Scale Production to Novel Clinical Modality. *Bioconjugate Chemistry*, **2016**, 27, 855-62	6.3	54
98	Fluoxetine and reversal of multidrug resistance. *Cancer Letters*, **2006**, 237, 180-7	9.9	54
97	Overcoming multidrug resistance with nanomedicines. *Expert Opinion on Drug Delivery*, **2015**, 12, 223-388		51
96	A daunting task: manipulating leukocyte function with RNAi. *Immunological Reviews*, **2013**, 253, 185-97	11.3	51
95	Monoclonal antibody-based molecular imaging strategies and theranostic opportunities. *Theranostics*, **2020**, 10, 938-955	12.1	50
94	Modulation of Immune Response Using Engineered Nanoparticle Surfaces. *Small*, **2016**, 12, 76-82	11	50
93	Nanomedicine as an emerging platform for metastatic lung cancer therapy. *Cancer and Metastasis Reviews*, **2015**, 34, 291-301	9.6	48
92	Tumor targeting profiling of hyaluronan-coated lipid based-nanoparticles. *Nanoscale*, **2014**, 6, 3742-52	7.7	48
91	AL-57, a ligand-mimetic antibody to integrin LFA-1, reveals chemokine-induced affinity up-regulation in lymphocytes. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 13991-6	11.5	45
90	Triggered-release polymeric conjugate micelles for on-demand intracellular drug delivery. *Nanotechnology*, **2015**, 26, 115101	3.4	44
89	Toxicity profiling of several common RNAi-based nanomedicines: a comparative study. *Drug Delivery and Translational Research*, **2014**, 4, 96-103	6.2	43
88	Treatment of resistant human colon cancer xenografts by a fluoxetine-doxorubicin combination enhances therapeutic responses comparable to an aggressive bevacizumab regimen. *Cancer Letters* , **2009**, 274, 118-25	9.9	40

87	Modulating cancer multidrug resistance by sertraline in combination with a nanomedicine. *Cancer Letters*, **2014**, 354, 290-8	9.9	39
86	Quaternized starch-based carrier for siRNA delivery: from cellular uptake to gene silencing. *Journal of Controlled Release*, **2014**, 185, 109-20	11.7	39
85	Cytosolic delivery of nucleic acids: The case of ionizable lipid nanoparticles. *Bioengineering and Translational Medicine*, **2021**, 6, e10213	14.8	38
84	RNAi nanomedicines: challenges and opportunities within the immune system. *Nanotechnology*, **2010**, 21, 232001	3.4	37
83	Physicochemical evaluation of a stability-driven approach to drug entrapment in regular and in surface-modified liposomes. *Archives of Biochemistry and Biophysics*, **2000**, 383, 185-90	4.1	37
82	Comprehensive and Systematic Analysis of the Immunocompatibility of Polyelectrolyte Capsules. *Bioconjugate Chemistry*, **2017**, 28, 556-564	6.3	36
81	Current Progress in Non-viral RNAi-Based Delivery Strategies to Lymphocytes. *Molecular Therapy*, **2017**, 25, 1491-1500	11.7	33
80	Design of SARS-CoV-2 hFc-Conjugated Receptor-Binding Domain mRNA Vaccine Delivered Lipid Nanoparticles. *ACS Nano*, **2021**, 15, 9627-9637	16.7	32
79	Grand challenges in modulating the immune response with RNAi nanomedicines. *Nanomedicine*, **2011**, 6, 1771-85	5.6	30
78	Systemic siRNA delivery to leukocyte-implicated diseases. *Cell Cycle*, **2009**, 8, 853-9	4.7	30
77	Harnessing nanomedicine for therapeutic intervention in glioblastoma. *Expert Opinion on Drug Delivery*, **2016**, 13, 1573-1582	8	29
76	RNA nanomedicines: the next generation drugs?. *Current Opinion in Biotechnology*, **2016**, 39, 28-34	11.4	28
75	eIF3c: a potential therapeutic target for cancer. *Cancer Letters*, **2013**, 336, 158-66	9.9	28
74	Harnessing nanomedicine for mucosal theranostics--a silver bullet at last?. *ACS Nano*, **2013**, 7, 2883-90	16.7	26
73	Polysarcosine-Functionalized Lipid Nanoparticles for Therapeutic mRNA Delivery. *ACS Applied Nano Materials*, **2020**, 3, 10634-10645	5.6	26
72	Advanced Strategies in Immune Modulation of Cancer Using Lipid-Based Nanoparticles. *Frontiers in Immunology*, **2017**, 8, 69	8.4	25
71	Precision medicine--delivering the goods?. *Cancer Letters*, **2014**, 352, 2-3	9.9	24
70	RNA inhibition highlights cyclin D1 as a potential therapeutic target for mantle cell lymphoma. *PLoS ONE*, **2012**, 7, e43343	3.7	24

69	Genetic perturbation of the putative cytoplasmic membrane-proximal salt bridge aberrantly activates alpha(4) integrins. *Blood*, **2008**, 112, 5007-15	2.2	24
68	Therapeutic mRNA delivery to leukocytes. *Journal of Controlled Release*, **2019**, 305, 165-175	11.7	22
67	Cationic Amphiphilic Drugs Boost the Lysosomal Escape of Small Nucleic Acid Therapeutics in a Nanocarrier-Dependent Manner. *ACS Nano*, **2020**, 14, 4774-4791	16.7	22
66	Assessing cellular toxicities in fibroblasts upon exposure to lipid-based nanoparticles: a high content analysis approach. *Nanotechnology*, **2011**, 22, 494016	3.4	22
65	Leukocyte-specific siRNA delivery revealing IRF8 as a potential anti-inflammatory target. *Journal of Controlled Release*, **2019**, 313, 33-41	11.7	21
64	Structural profiling and biological performance of phospholipid-hyaluronan functionalized single-walled carbon nanotubes. *Journal of Controlled Release*, **2013**, 170, 295-305	11.7	21
63	Induction of therapeutic gene silencing in leukocyte-implicated diseases by targeted and stabilized nanoparticles: a mini-review. *Journal of Controlled Release*, **2010**, 148, 63-68	11.7	21
62	Detection of intestinal inflammation by MicroPET imaging using a (64)Cu-labeled anti-beta(7) integrin antibody. *Inflammatory Bowel Diseases*, **2010**, 16, 1458-66	4.5	21
61	Advances in RNAi therapeutic delivery to leukocytes using lipid nanoparticles. *Journal of Drug Targeting*, **2016**, 24, 780-786	5.4	21
60	Targeted lipid nanoparticles for RNA therapeutics and immunomodulation in leukocytes. *Advanced Drug Delivery Reviews*, **2020**, 159, 364-376	18.5	21
59	Principles for designing an optimal mRNA lipid nanoparticle vaccine. *Current Opinion in Biotechnology*, **2021**, 73, 329-336	11.4	19
58	Harnessing RNAi nanomedicine for precision therapy. *Molecular and Cellular Therapies*, **2014**, 2, 5		18
57	Engineering lymphocytes with RNAi. *Advanced Drug Delivery Reviews*, **2019**, 141, 55-66	18.5	18
56	Antibody-mediated delivery of siRNAs for anti-HIV therapy. *Methods in Molecular Biology*, **2011**, 721, 339-53	1.4	16
55	Serum chemokine network correlates with chemotherapy in non-small cell lung cancer. *Cancer Letters*, **2015**, 365, 57-67	9.9	15
54	SNP detection in mRNA in living cells using allele specific FRET probes. *PLoS ONE*, **2013**, 8, e72389	3.7	15
53	Colitis ImmunoPET: Defining Target Cell Populations and Optimizing Pharmacokinetics. *Inflammatory Bowel Diseases*, **2016**, 22, 529-38	4.5	15
52	Immunomodulation of hematological malignancies using oligonucleotides based-nanomedicines. *Journal of Controlled Release*, **2016**, 244, 149-156	11.7	15

51	Platelet mimicry: The emperor's new clothes?. *Nanomedicine: Nanotechnology, Biology, and Medicine*, **2016**, 12, 245-8	6	14
50	Progress and challenges towards CRISPR/Cas clinical translation. *Advanced Drug Delivery Reviews*, **2020**, 154-155, 176-186	18.5	14
49	Liposomes and other assemblies as drugs and nano-drugs: from basic and translational research to the clinics. *Journal of Controlled Release*, **2012**, 160, 115-6	11.7	13
48	ECM-based macroporous sponges release essential factors to support the growth of hematopoietic cells. *Journal of Controlled Release*, **2017**, 257, 84-90	11.7	12
47	Metastability in lipid based particles exhibits temporally deterministic and controllable behavior. *Scientific Reports*, **2015**, 5, 9481	4.9	12
46	Conformation-sensitive targeting of lipid nanoparticles for RNA therapeutics. *Nature Nanotechnology*, **2021**, 16, 1030-1038	28.7	12
45	Targeting central nervous system pathologies with nanomedicines. *Journal of Drug Targeting*, **2019**, 27, 542-554	5.4	12
44	Bioinspired artificial exosomes based on lipid nanoparticles carrying let-7b-5p promote angiogenesis in vitro and in vivo. *Molecular Therapy*, **2021**, 29, 2239-2252	11.7	12
43	Liposomes, lipid biophysics, and sphingolipid research: from basic to translation research. *Chemistry and Physics of Lipids*, **2012**, 165, 363-4	3.7	11
42	Enhanced bioavailability of polyaromatic hydrocarbons in the form of mucin complexes. *Chemical Research in Toxicology*, **2011**, 24, 314-20	4	11
41	The human P-glycoprotein transporter enhances the type I interferon response to Listeria monocytogenes infection. *Infection and Immunity*, **2015**, 83, 2358-68	3.7	10
40	Hierarchical theranostic nanomedicine: MRI contrast agents as a physical vehicle anchor for high drug loading and triggered on-demand delivery. *Journal of Materials Chemistry B*, **2018**, 6, 1995-2003	7.3	10
39	An ovarian spheroid based tumor model that represents vascularized tumors and enables the investigation of nanomedicine therapeutics. *Nanoscale*, **2020**, 12, 1894-1903	7.7	10
38	Integrin-targeted nanoparticles for siRNA delivery. *Methods in Molecular Biology*, **2012**, 757, 497-507	1.4	9
37	Challenges in IBD Research: Novel Technologies. *Inflammatory Bowel Diseases*, **2019**, 25, S24-S30	4.5	8
36	Resveratrol Enhances mRNA and siRNA Lipid Nanoparticles Primary CLL Cell Transfection. *Pharmaceutics*, **2020**, 12,	6.4	8
35	Molecular and Cellular Therapies: New challenges and opportunities. *Molecular and Cellular Therapies*, **2013**, 1, 1		8
34	Targeting anthracycline-resistant tumor cells with synthetic aloe-emodin glycosides. *ACS Medicinal Chemistry Letters*, **2011**, 2, 528-31	4.3	8

33	Lipid Nanoparticle RBD-hFc mRNA Vaccine Protects hACE2 Transgenic Mice against a Lethal SARS-CoV-2 Infection. *Nano Letters*, **2021**, 21, 4774-4779	11.5	8
32	Investigation of pH-Responsiveness inside Lipid Nanoparticles for Parenteral mRNA Application Using Small-Angle X-ray Scattering. *Langmuir*, **2020**, 36, 13331-13341	4	6
31	Therapeutic inhibitory RNA in head and neck cancer via functional targeted lipid nanoparticles. *Journal of Controlled Release*, **2021**, 337, 378-389	11.7	6
30	Structural Characterization of the Drug Translocation Path of MRP1/ABCC1. *Israel Journal of Chemistry*, **2014**, 54, 1382-1393	3.4	5
29	Roadmap on nanomedicine. *Nanotechnology*, **2021**, 32, 012001	3.4	5
28	Featuring the special issue guest editor: Dan Peer, Ph.D. *Cancer Letters*, **2014**, 352, 1	9.9	4
27	Integrin-targeted stabilized nanoparticles for an efficient delivery of siRNAs in vitro and in vivo. *Methods in Molecular Biology*, **2012**, 820, 105-16	1.4	4
26	Systemic Modulation of Lymphocyte Subsets Using siRNAs Delivered via Targeted Lipid Nanoparticles. *Methods in Molecular Biology*, **2019**, 1974, 151-159	1.4	3
25	A tissue chamber chip for assessing nanoparticle mobility in the extravascular space. *Biomedical Microdevices*, **2019**, 21, 41	3.7	3
24	Personalized Tissue Implants: Personalized Hydrogels for Engineering Diverse Fully Autologous Tissue Implants (Adv. Mater. 1/2019). *Advanced Materials*, **2019**, 31, 1970007	24	3
23	Zooming in on selectins in cancer. *Science Translational Medicine*, **2016**, 8, 345fs11	17.5	3
22	Fe3O4 Nanoparticles and Paraffin Wax as Phase Change Materials Embedded in Polymer Matrixes for Temperature-Controlled Magnetic Hyperthermia. *ACS Applied Nano Materials*, **2021**, 4, 11187-11198	5.6	3
21	Nanoparticles Accumulate in the Female Reproductive System during Ovulation Affecting Cancer Treatment and Fertility.. *ACS Nano*, **2022**,	16.7	3
20	Orchestrating a Symphony on a Single Conjugate: Aptamer Targeting, Gene Silencing, and Immunomodulation to Enhance Antitumor Response. *Molecular Therapy*, **2017**, 25, 5-7	11.7	2
19	Dielectrophoretic characterization of cells in a stationary nanoliter droplet array with generated chemical gradients. *Biomedical Microdevices*, **2015**, 17, 91	3.7	2
18	RNA interference-based therapeutics and diagnostics. *Drug Delivery and Translational Research*, **2014**, 4, 1-2	6.2	2
17	Dual-Targeted Lipid Nanotherapeutic Boost for Chemo-Immunotherapy of Cancer.. *Advanced Materials*, **2022**, e2106350	24	2
16	Therapeutic Gene Silencing Using Targeted Lipid Nanoparticles in Metastatic Ovarian Cancer. *Small*, **2021**, 17, e2100287	11	2

List of Publications

15	Targeting Cancer Using Nanocarriers. *Advances in Delivery Science and Technology*, **2016**, 131-155		1
14	IKAP/hELP1 down-regulation in neuroblastoma cells causes enhanced cell adhesion mediated by contactin overexpression. *Cell Adhesion and Migration*, **2010**, 4, 541-50	3.2	1
13	Nanocarriers delivering RNAi to cancer cells: from challenge to cautious optimism. *Therapy: Open Access in Clinical Medicine*, **2009**, 6, 293-296		1
12	Delivery strategies of RNA therapeutics to leukocytes.. *Journal of Controlled Release*, **2022**, 342, 362-371	11.7	1
11	Design of SARS-CoV-2 RBD mRNA Vaccine Using Novel Ionizable Lipids		1
10	Quantitative analysis of recombinant glucocerebrosidase brain delivery via lipid nanoparticles. *Nano Futures*, **2018**, 2, 045003	3.6	0
9	RNA Delivery: A Combinatorial Library of Lipid Nanoparticles for RNA Delivery to Leukocytes (Adv. Mater. 12/2020). *Advanced Materials*, **2020**, 32, 2070093	24	
8	Nanomedicines for Systemic Delivery of RNAi Therapeutics. *Advances in Delivery Science and Technology*, **2013**, 127-142		
7	RNAi Nanomedicines toward Advancing Personalized Medicine **2014**, 59-79		
6	Gene Silencing: Therapeutic Gene Silencing Using Targeted Lipid Nanoparticles in Metastatic Ovarian Cancer (Small 19/2021). *Small*, **2021**, 17, 2170086	11	
5	Future Outlook of Nanopharmacy: Challenges and Opportunities **2016**, 735-742		
4	Omics-Based Nanopharmacy: Powerful Tools Toward Precision Medicine **2016**, 81-100		
3	Gene Silencing in the Right Place at the Right Time. *Molecular Therapy*, **2018**, 26, 2539-2541	11.7	
2	Delivery strategies of RNA therapeutics for ex vivo and in vivo B-cell malignancies **2022**, 117-146		
1	Extrahepatic delivery of RNA to immune cells **2022**, 57-86		